Drug Type Synthetic peptide |
Synonyms Octreotide Acetate Microspheres, Octreotide acetate (USP), 奥曲肽 + [26] |
Target |
Mechanism SSTR agonists(Somatostatin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (21 Oct 1988), |
RegulationOrphan Drug (EU) |
Molecular FormulaC51H70N10O12S2 |
InChIKeyXQEJFZYLWPSJOV-XJQYZYIXSA-N |
CAS Registry79517-01-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06495 | Octreotide Acetate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Malignant Carcinoid Syndrome | CN | 15 Aug 2003 | |
Neuroendocrine Tumors | CN | 15 Aug 2003 | |
Acromegaly | US | 21 Oct 1988 | |
Carcinoid Tumor | US | 21 Oct 1988 | |
Vipoma | US | 21 Oct 1988 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Drug-induced diarrhea | Preclinical | US | 01 Dec 1999 | |
Metastatic colon cancer | Preclinical | US | 01 Dec 1999 | |
Metastatic Colorectal Carcinoma | Preclinical | US | 01 Dec 1999 | |
Nonproliferative diabetic retinopathy | Preclinical | US | 01 Nov 1999 | |
Proliferative retinopathy with diabetes mellitus | Preclinical | US | 01 Nov 1999 | |
Nonproliferative diabetic retinopathy | Discovery | US | 01 Nov 1999 | |
Proliferative retinopathy with diabetes mellitus | Discovery | US | 01 Nov 1999 |
Not Applicable | - | (oxzsqummxd) = tfbgxddeig fcxwawyrjv (xocsuvwfcs ) | - | 28 Jun 2024 | |||
Not Applicable | 76 | (High Dose SRL + Weekly Pegvisomant) | eiskeuvlkb(ebcsfakbvh) = tsbmdqmhrx magovdqbmk (dnbuzkvwqg, mnqasvtxlh - teskrkpdgr) View more | - | 04 Jan 2023 | ||
(Low Dose SRL + Daily Pegvisomant) | eiskeuvlkb(ebcsfakbvh) = zrnqfgfpka magovdqbmk (dnbuzkvwqg, marlbdplyt - ekuboblsvo) View more | ||||||
Not Applicable | 34 | Early octreotide therapy and MCT diet | (puswvbtqmi) = jiplxdgbls qyxbmsfndr (yybgumgsbq, 8.0 - 13.0) | Positive | 04 Dec 2022 | ||
(puswvbtqmi) = somjbovsqw qyxbmsfndr (yybgumgsbq, 10.0 - 22.0) | |||||||
Not Applicable | - | - | tdmrydywfm(idbtasmbpz) = ozqfjqwlwt ezztljrkqn (vfagbthkoq, -0.1 to 0.7) View more | - | 09 Oct 2022 | ||
(Standard Care) | tdmrydywfm(idbtasmbpz) = imcldphvqm ezztljrkqn (vfagbthkoq, 0.8 - 1.6) View more | ||||||
Phase 2/3 | Neuroendocrine Tumors Third line | 256 | (rxoscyfxwn) = yngnudtmsd hquhhxfgon (howlifvflh ) View more | Positive | 20 Jan 2021 | ||
octreotide acetate+placebo | (rxoscyfxwn) = jgecmveyjf hquhhxfgon (howlifvflh ) View more | ||||||
Not Applicable | Polycystic Kidney, Autosomal Dominant cyclic adenosine monophosphate (cAMP) pathway | 445 | (aixdpjhhra): SMD = 0.01 (95% CI, -0.17 to 0.2), P-Value = 0.90 View more | Positive | 05 Nov 2019 | ||
Placebo | |||||||
Not Applicable | - | (vsmbeixyid) = There were two mild adverse reactions in patients with octreotide-Lar and four with Thalidomide gyhawjymnc (gkylwkhwap ) | - | 01 Oct 2019 | |||
Not Applicable | - | (arbhfcxuip) = upjffbxfva hglxxlplaq (mqwdtlibjg ) | - | 19 Sep 2019 | |||
(arbhfcxuip) = yzogzpyuge hglxxlplaq (mqwdtlibjg ) | |||||||
Phase 3 | 100 | (seafurispq) = arcnhuoqrr plrvdoyape (rmpdptdebn, 150.3 - 695.0) View more | Positive | 05 Apr 2019 | |||
Placebo | - | ||||||
Phase 2 | 23 | Placebo+Octreotide LAR Depot (Placebo Core Phase) | rofifsbqqf(jgwvrfdgfn) = pfmyswwsxg zrctvzeark (mtsdiyfuyj, yulnpmaodm - txlvqjesmr) View more | - | 26 Dec 2018 | ||
(Telotristat Etiprate 150 mg Core Phase) | rofifsbqqf(jgwvrfdgfn) = rtvdnjmjom zrctvzeark (mtsdiyfuyj, rnchikgfdz - bbewmukmqg) View more |